Gentris Corporation, a provider of pharmacogenomics services, is now part of the Personalized Medicine Coalition.
The educational and advocacy group is designed to promote personalized medicine. It was formed in 2003 by more than 20 pharmaceutical, biotechnology, diagnostic and information technology companies.
“The Coalition brings together leaders from every sector involved in personalized medicine,” said Michael Murphy, president and chief executive officer of Gentris. “Together we will educate and explore issues that may require new or revised public policy.”